10 Best Undervalued Dividend Stocks Insiders Are Buying for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The 2025 market landscape is shaped by persistent macroeconomic uncertainty, sector rotation, and a renewed focus on company fundamentals. At ValueSense, our stock selection methodology combines quantitative screening—using intrinsic value, quality ratings, and financial health metrics—with qualitative analysis of growth catalysts and risk factors[1][2]. Our platform leverages AI-powered tools to synthesize financial data, earnings sentiment, and sector trends, ensuring a balanced, diversified watchlist[1]. Each stock featured below meets strict criteria for value, quality, and potential upside, as determined by ValueSense’s proprietary models and research[2].
Featured Stock Analysis
Stock #1: Uber Technologies, Inc. (UBER)
| Metric | Value |
|---|---|
| Market Cap | $201.9B |
| Quality Rating | 7.5 |
| Intrinsic Value | $201.7 |
| 1Y Return | 33.9% |
| Revenue | $47.3B |
| Free Cash Flow | $8,540.0M |
| Revenue Growth | 18.2% |
| FCF margin | 18.0% |
| Gross margin | 39.7% |
| ROIC | 66.4% |
| Total Debt to Equity | 52.2% |
Investment Thesis
Uber Technologies stands out as a leader in the global mobility and delivery sectors, leveraging its dominant platform to drive robust revenue growth and margin expansion. With a market cap of $201.9B and a 1-year return of 33.9%, Uber’s business model benefits from network effects and operational scale. The company’s intrinsic value of $201.7 suggests alignment with its current valuation, while a quality rating of 7.5 reflects strong fundamentals and execution.
Uber’s financials are compelling: $47.3B in revenue, $8.54B in free cash flow, and an impressive 18.2% revenue growth rate. Its FCF margin 18.0% and gross margin 39.7% indicate efficient operations, while a remarkable ROIC of 66.4% highlights capital allocation strength. Debt levels (Total Debt to Equity: 52.2%) are manageable within the context of its cash generation.
Key Catalysts
- Continued expansion in delivery and mobility services
- Strong free cash flow supporting reinvestment and potential shareholder returns
- Ongoing margin improvement and operational leverage
- Global platform scale and technology leadership
Risk Factors
- Regulatory challenges in key markets
- Competitive pressures from both traditional and emerging mobility players
- Exposure to macroeconomic cycles affecting consumer demand
Stock #2: Intel Corporation (INTC)
| Metric | Value |
|---|---|
| Market Cap | $180.5B |
| Quality Rating | 5.1 |
| Intrinsic Value | $74.5 |
| 1Y Return | 85.8% |
| Revenue | $53.4B |
| Free Cash Flow | ($7,251.0M) |
| Revenue Growth | (1.5%) |
| FCF margin | (13.6%) |
| Gross margin | 35.8% |
| ROIC | (1.3%) |
| Total Debt to Equity | 39.9% |
Investment Thesis
Intel is navigating a critical transformation as it seeks to regain semiconductor leadership amid fierce global competition. With a $180.5B market cap and a stellar 1-year return of 85.8%, Intel’s turnaround efforts are gaining traction. The company’s intrinsic value of $74.5 points to potential upside, especially as it invests in next-generation manufacturing and AI-driven chip design.
Despite a revenue decline (-1.5% YoY) to $53.4B and negative free cash flow -$7.25B, Intel’s gross margin 35.8% and manageable debt (Total Debt to Equity: 39.9%) provide a foundation for recovery. The quality rating of 5.1 reflects transitional challenges, but also the potential for significant improvement as new products ramp and capital investments bear fruit.
Key Catalysts
- Acceleration of AI and data center chip adoption
- Strategic partnerships and government support for domestic manufacturing
- Product roadmap execution and process technology advancements
Risk Factors
- Execution risk in manufacturing and product launches
- Intense competition from AMD, NVIDIA, and global foundries
- Ongoing negative free cash flow and margin pressure
Stock #3: The Boeing Company (BA)
| Metric | Value |
|---|---|
| Market Cap | $152.1B |
| Quality Rating | 4.8 |
| Intrinsic Value | $231.4 |
| 1Y Return | 34.6% |
| Revenue | $80.8B |
| Free Cash Flow | ($4,364.0M) |
| Revenue Growth | 10.2% |
| FCF margin | (5.4%) |
| Gross margin | 1.1% |
| ROIC | (7.9%) |
| Total Debt to Equity | (646.5%) |
Investment Thesis
Boeing remains a cornerstone of the global aerospace industry, with a $152.1B market cap and a 1-year return of 34.6%. The company’s intrinsic value of $231.4 suggests substantial upside if operational challenges are resolved. Boeing’s $80.8B in revenue and 10.2% revenue growth highlight resilient demand for commercial aircraft, though profitability remains under pressure.
The company’s negative free cash flow -$4.36B, slim gross margin 1.1%, and high leverage (Total Debt to Equity: -646.5%) reflect ongoing recovery efforts post-pandemic and after several high-profile setbacks. The quality rating of 4.8 underscores the need for operational improvements, but also the potential for a turnaround as supply chain issues abate and deliveries ramp up.
Key Catalysts
- Recovery in global air travel and aircraft deliveries
- Resolution of supply chain and production bottlenecks
- Defense and space segment growth
Risk Factors
- High debt burden and negative cash flow
- Regulatory and reputational risks from past safety incidents
- Execution risk in ramping production and restoring profitability
Stock #4: Pfizer Inc. (PFE)
| Metric | Value |
|---|---|
| Market Cap | $140.1B |
| Quality Rating | 6.3 |
| Intrinsic Value | $39.3 |
| 1Y Return | -10.1% |
| Revenue | $63.8B |
| Free Cash Flow | $12.4B |
| Revenue Growth | 14.7% |
| FCF margin | 19.5% |
| Gross margin | 66.2% |
| ROIC | 10.6% |
| Total Debt to Equity | 69.4% |
Investment Thesis
Pfizer is a global pharmaceutical leader with a $140.1B market cap and a quality rating of 6.3. Despite a -10.1% 1-year return, Pfizer’s $63.8B in revenue and strong free cash flow $12.4B position it well for long-term value creation. The company’s intrinsic value of $39.3 suggests potential undervaluation, especially as it pivots from pandemic-era highs to a diversified pipeline.
Pfizer’s 14.7% revenue growth, robust FCF margin 19.5%, and high gross margin 66.2% underscore its profitability. ROIC of 10.6% and a Total Debt to Equity of 69.4% reflect prudent capital management and financial flexibility.
Key Catalysts
- Advancements in oncology and rare disease treatments
- Strategic acquisitions and pipeline expansion
- Strong cash flow supporting R&D and shareholder returns
Risk Factors
- Patent expirations and generic competition
- Regulatory and pricing pressures
- Post-pandemic revenue normalization
Stock #5: Medtronic plc (MDT)
| Metric | Value |
|---|---|
| Market Cap | $116.2B |
| Quality Rating | 6.7 |
| Intrinsic Value | $120.6 |
| 1Y Return | 2.5% |
| Revenue | $34.2B |
| Free Cash Flow | $5,303.0M |
| Revenue Growth | 5.0% |
| FCF margin | 15.5% |
| Gross margin | 63.4% |
| ROIC | 8.2% |
| Total Debt to Equity | 59.4% |
Investment Thesis
Medtronic is a leading medical device company with a $116.2B market cap and a quality rating of 6.7. Its $34.2B in revenue, $5.3B in free cash flow, and 5.0% revenue growth highlight steady performance in a defensive sector. The intrinsic value of $120.6 and a modest 1-year return 2.5% suggest room for re-rating as healthcare innovation accelerates.
Medtronic’s FCF margin 15.5%, gross margin 63.4%, and ROIC 8.2% indicate operational strength. The company’s Total Debt to Equity of 59.4% is manageable, supporting ongoing investment in R&D and product launches.
Key Catalysts
- Innovation in minimally invasive and robotic surgery
- Expansion in emerging markets
- Aging global population driving demand
Risk Factors
- Regulatory hurdles for new device approvals
- Pricing pressures from payers and competitors
- Currency and macroeconomic headwinds
Stock #6: ConocoPhillips (COP)
| Metric | Value |
|---|---|
| Market Cap | $111.7B |
| Quality Rating | 5.9 |
| Intrinsic Value | $113.5 |
| 1Y Return | -17.6% |
| Revenue | $58.3B |
| Free Cash Flow | $6,923.0M |
| Revenue Growth | 3.5% |
| FCF margin | 11.9% |
| Gross margin | 28.7% |
| ROIC | 9.3% |
| Total Debt to Equity | 35.9% |
Investment Thesis
ConocoPhillips is a major energy producer with a $111.7B market cap and a quality rating of 5.9. Despite a -17.6% 1-year return, the company’s $58.3B in revenue and $6.92B in free cash flow provide a solid foundation. The intrinsic value of $113.5 suggests alignment with current market pricing, while an 11.9% FCF margin and 28.7% gross margin highlight operational efficiency.
ConocoPhillips’ 3.5% revenue growth and ROIC of 9.3% reflect disciplined capital allocation. Debt levels (Total Debt to Equity: 35.9%) are moderate for the sector, supporting resilience through commodity cycles.
Key Catalysts
- Strategic asset portfolio and disciplined capital spending
- Shareholder returns via dividends and buybacks
- Exposure to global energy demand recovery
Risk Factors
- Volatility in oil and gas prices
- Regulatory and ESG pressures
- Geopolitical risks in key operating regions
Stock #7: Enbridge Inc. (ENB)
| Metric | Value |
|---|---|
| Market Cap | $101.6B |
| Quality Rating | 5.4 |
| Intrinsic Value | $75.2 |
| 1Y Return | 18.9% |
| Revenue | CA$64.5B |
| Free Cash Flow | CA$4,631.0M |
| Revenue Growth | 48.5% |
| FCF margin | 7.2% |
| Gross margin | 32.6% |
| ROIC | 5.1% |
| Total Debt to Equity | 147.8% |
Investment Thesis
Enbridge is a leading North American energy infrastructure company with a $101.6B market cap and a quality rating of 5.4. The company’s CA$64.5B in revenue, CA$4.63B in free cash flow, and a strong 48.5% revenue growth rate underscore its scale and stability. An intrinsic value of $75.2 and an 18.9% 1-year return highlight investor confidence.
Enbridge’s FCF margin 7.2%, gross margin 32.6%, and ROIC 5.1% reflect steady performance. However, a high Total Debt to Equity ratio 147.8% warrants monitoring, given the capital-intensive nature of its business.
Key Catalysts
- Expansion of pipeline and renewable energy assets
- Stable cash flows from regulated operations
- Dividend growth potential
Risk Factors
- Regulatory and environmental challenges
- High leverage and interest rate sensitivity
- Commodity price exposure
Stock #8: United Parcel Service, Inc. (UPS)
| Metric | Value |
|---|---|
| Market Cap | $81.9B |
| Quality Rating | 6.0 |
| Intrinsic Value | $138.0 |
| 1Y Return | -26.1% |
| Revenue | $89.4B |
| Free Cash Flow | $4,396.0M |
| Revenue Growth | (1.3%) |
| FCF margin | 4.9% |
| Gross margin | 18.1% |
| ROIC | 12.6% |
| Total Debt to Equity | 184.3% |
Investment Thesis
UPS is a global logistics leader with an $81.9B market cap and a quality rating of 6.0. Despite a -26.1% 1-year return, UPS’s $89.4B in revenue and $4.4B in free cash flow demonstrate its scale and cash generation. The intrinsic value of $138.0 suggests potential undervaluation as e-commerce and global trade trends persist.
UPS’s FCF margin 4.9%, gross margin 18.1%, and ROIC 12.6% reflect operational efficiency. However, a high Total Debt to Equity ratio 184.3% highlights leverage risk, particularly in a cyclical industry.
Key Catalysts
- Growth in e-commerce and last-mile delivery
- Operational efficiency initiatives
- Global expansion and automation
Risk Factors
- Cyclical demand and economic sensitivity
- Labor costs and union negotiations
- High leverage and interest rate exposure
Stock #9: Elevance Health Inc. (ELV)
| Metric | Value |
|---|---|
| Market Cap | $71.6B |
| Quality Rating | 6.1 |
| Intrinsic Value | $295.5 |
| 1Y Return | -21.2% |
| Revenue | $194.8B |
| Free Cash Flow | $3,767.0M |
| Revenue Growth | 12.0% |
| FCF margin | 1.9% |
| Gross margin | 77.7% |
| ROIC | 14.7% |
| Total Debt to Equity | 2.1% |
Investment Thesis
Elevance Health is a major health insurance provider with a $71.6B market cap and a quality rating of 6.1. The company’s $194.8B in revenue, $3.77B in free cash flow, and 12.0% revenue growth highlight its scale and growth trajectory. The intrinsic value of $295.5 and a -21.2% 1-year return suggest potential for a value rebound.
Elevance’s FCF margin 1.9%, gross margin 77.7%, and ROIC 14.7% indicate strong profitability. A low Total Debt to Equity ratio 2.1% provides financial flexibility for future growth.
Key Catalysts
- Expansion in government and commercial health plans
- Technology-driven cost efficiencies
- Aging population and increased healthcare demand
Risk Factors
- Regulatory and reimbursement risk
- Competitive pressures in managed care
- Policy changes affecting healthcare coverage
Stock #10: CSX Corporation (CSX)
| Metric | Value |
|---|---|
| Market Cap | $67.1B |
| Quality Rating | 6.4 |
| Intrinsic Value | $37.5 |
| 1Y Return | 7.9% |
| Revenue | $15.0B |
| Free Cash Flow | $3,777.0M |
| Revenue Growth | 2.1% |
| FCF margin | 25.2% |
| Gross margin | 36.6% |
| ROIC | 18.8% |
| Total Debt to Equity | 12.3% |
Investment Thesis
CSX is a leading North American railroad operator with a $67.1B market cap and a quality rating of 6.4. The company’s $15.0B in revenue, $3.78B in free cash flow, and 2.1% revenue growth reflect steady performance in a defensive sector. The intrinsic value of $37.5 and a 7.9% 1-year return highlight its appeal as a core infrastructure holding.
CSX’s FCF margin 25.2%, gross margin 36.6%, and ROIC 18.8% underscore operational excellence. A low Total Debt to Equity ratio 12.3% supports ongoing investment and shareholder returns.
Key Catalysts
- Efficiency gains from precision scheduled railroading
- Growth in intermodal and bulk freight
- Infrastructure investment tailwinds
Risk Factors
- Economic sensitivity affecting freight volumes
- Regulatory and labor challenges
- Competition from trucking and alternative transport
Portfolio Diversification Insights
This watchlist spans technology, healthcare, energy, industrials, and transportation, providing broad sector diversification. Exposure to both growth (Uber, Intel) and defensive (Pfizer, Medtronic, CSX) names helps balance risk and return. Energy (ConocoPhillips, Enbridge) and logistics (UPS) add cyclical and yield-oriented components, while Elevance Health offers healthcare services exposure. This mix aims to reduce portfolio volatility and capture opportunities across market cycles.
Market Timing & Entry Strategies
Entry timing should consider sector rotation, earnings season, and macroeconomic signals. For growth stocks, look for technical breakouts or post-earnings pullbacks; for defensive and yield names, consider averaging in during market weakness. Use ValueSense’s intrinsic value and quality ratings to identify attractive entry points, and monitor news for catalysts or risk events. Diversifying entry over time can help manage volatility and reduce timing risk.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s proprietary screening tools, which combine intrinsic value analysis, quality ratings, and sector diversification to identify companies with strong fundamentals and potential upside[1][2].
Q2: What's the best stock from this list?
Each stock offers unique strengths; Uber and Intel currently stand out for growth potential, while Pfizer and CSX provide defensive qualities. The “best” stock depends on individual investment goals and risk tolerance.
Q3: Should I buy all these stocks or diversify?
Diversification across sectors and business models is recommended for risk management. This watchlist is designed to provide balanced exposure, but allocation should reflect your personal strategy and financial situation.
Q4: What are the biggest risks with these picks?
Risks include sector-specific headwinds (regulation, competition), macroeconomic uncertainty, and company-specific execution challenges. Review each stock’s risk factors and monitor for changes in fundamentals.
Q5: When is the best time to invest in these stocks?
Optimal timing varies by stock and market conditions. Consider entering positions gradually, using pullbacks or post-earnings volatility, and leverage ValueSense’s intrinsic value assessments for guidance.